AngioDynamics Inc ANGO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results
-
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes
-
AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024
-
AngioDynamics Announces CE Mark Approval in Europe for the Auryon System
-
AngioDynamics to Participate in Upcoming Investor Conferences
-
AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results
-
AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024
-
AngioDynamics Shares Rise 10% After FDA Clears AlphaVac F18 System
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.01
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Stock Style Box
- Small Value
- Total Number of Employees
- 748
- Website
- https://www.angiodynamics.com
Comparables
Valuation
Metric
|
ANGO
|
688016
|
603301
|
---|---|---|---|
Price/Earnings (Normalized) | — | 22.39 | 24.38 |
Price/Book Value | 1.50 | 3.46 | 1.18 |
Price/Sales | 1.01 | 9.68 | 1.68 |
Price/Cash Flow | — | 19.38 | 10.16 |
Price/Earnings
ANGO
688016
603301
Financial Strength
Metric
|
ANGO
|
688016
|
603301
|
---|---|---|---|
Quick Ratio | 1.38 | 8.91 | 1.57 |
Current Ratio | 2.12 | 9.53 | 2.24 |
Interest Coverage | — | 413.50 | 5.28 |
Quick Ratio
ANGO
688016
603301
Profitability
Metric
|
ANGO
|
688016
|
603301
|
---|---|---|---|
Return on Assets (Normalized) | −3.55% | 16.12% | 1.65% |
Return on Equity (Normalized) | −4.72% | 18.19% | 2.34% |
Return on Invested Capital (Normalized) | −4.97% | 17.54% | 1.91% |
Return on Assets
ANGO
688016
603301
Medical Instruments & Supplies Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Intuitive Surgical Inc
ISRG
| Zxgycdcf | Sjt | $172.9 Bil | |||
Becton Dickinson & Co
BDX
| Vxgchcbc | Ffhsr | $69.3 Bil | |||
Alcon Inc
ALC
| Sgwffqbcc | Rbryx | $49.2 Bil | |||
ResMed Inc
RMD
| Fykspnff | Ldpsmr | $35.1 Bil | |||
Coloplast AS ADR
CLPBY
| Kydhjpnv | Xxdf | $29.2 Bil | |||
West Pharmaceutical Services Inc
WST
| Fdvcfshsj | Njm | $21.7 Bil | |||
The Cooper Companies Inc
COO
| Xblzsch | Grshm | $21.5 Bil | |||
Hologic Inc
HOLX
| Xtqyxgpgd | Tlbyvl | $18.5 Bil | |||
Baxter International Inc
BAX
| Hjrwqqztp | Qlntwt | $18.4 Bil | |||
Align Technology Inc
ALGN
| Vkhnqgs | Kqjvrv | $17.8 Bil |